These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35524872)

  • 41. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
    Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
    Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.
    Chibaudel B; André T; Tournigand C; Louvet C; Benetkiewicz M; Larsen AK; de Gramont A
    Clin Colorectal Cancer; 2020 Sep; 19(3):200-208.e1. PubMed ID: 32303437
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
    J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
    J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
    Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
    JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
    Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E;
    Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
    Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
    Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
    Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
    Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
    Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Impact of Primary Tumor Location and
    Sato T; Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
    Anticancer Res; 2021 Aug; 41(8):3905-3915. PubMed ID: 34281853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.